Is Cancer Immunotherapy More Hype Than Hope?
DOI:
https://doi.org/10.28932/jmh.v2i6.2826Abstract
The immunosurveillance system in the human body can detect and eradicate abnormal cells. However, cancer cells can avoid immune destruction by exploiting the immunosuppression system. Extensive research has been done to find therapeutic agents that could reverse this condition. Novel drugs called checkpoint inhibitors have been developed and showed a promising result. Besides, “living’’ drug, an engineered T-cells which can accurately target cancer cells, has increased public attention in immunotherapy. These immunotherapies might bring a new era of cancer management, a highly effective and specific treatment with fewer adverse effects. Keywords: Immunosurveillance; T-Cell; Therapeutic agents; ImmunotherapiesDownloads
Download data is not yet available.
Downloads
Published
2020-08-31
How to Cite
1.
Lesmana R, Hadi EJ, Goenawan H. Is Cancer Immunotherapy More Hype Than Hope?. J. Med. Health [Internet]. 2020Aug.31 [cited 2024Dec.18];2(6). Available from: http://114.7.153.31/index.php/jmh/article/view/2826
Issue
Section
Articles
License
Authors who publish with this journal agree to the following terms:
- Authors retain the copyright and grant the journal right of first publication with the work
simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
